`
`
`
`
`
`
`
`
`
`
`
` Paper 54
`
`
` Entered: July 31, 2017
`
`Trials@uspto.gov
`571-272-7822
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`LUYE PHARMA GROUP LTD., LUYE PHARMA(USA) LTD.,
`SHANDONG LUYE PHARMACEUTICAL CO., LTD., and
`NANJING LUYE PHARMACEUTICAL CO., LTD.,
`Petitioner,
`
`v.
`
`ALKERMES PHARMA IRELAND LTD. and
`ALKERMES CONTROLLED THERAPEUTICS, INC.,
`Patent Owner.
`____________
`
`
`
`Case IPR2016-01096
`Patent 6,667,061 B2
`____________
`
`
`Before LORA M. GREEN, ROBERT A. POLLOCK, and
`JACQUELINE T. HARLOW, Administrative Patent Judges.
`
`GREEN, Administrative Patent Judge.
`
`
`
`ORDER
`Oral Hearing
`37 C.F.R. § 42.70
`
`
`
`
`
`
`
`IPR2016-01096
`Patent 6,667,061 B2
`
`
`We instituted the above-identified inter partes review on November
`30, 2016. Paper 13. The Scheduling Order set August 28, 2017, as the date
`for oral argument, if requested by either party. Paper 15. Petitioner and
`Patent Owner each requested an oral hearing pursuant to 37 C.F.R.
`§ 42.70(a). Papers 48, 49. The requests are granted.
`The hearing will commence at 1:00 PM Eastern Time, on
`Wednesday, August 28, 2017, and will be conducted at the USPTO
`Central Headquarters in Alexandria, Virginia (the ninth floor of Madison
`Building East, 600 Dulany Street, Alexandria, Virginia, 22314). The
`hearing will be open to the public for in-person attendance that will be
`accommodated on a first-come, first-served basis.
`Each party will have 45 minutes of argument time. Petitioner bears
`the ultimate burden of proof that the challenged claims are unpatentable.
`Accordingly, Petitioner will proceed first to present its case regarding the
`challenged claims for which the Board instituted trial. Patent Owner will
`then have an opportunity to respond to Petitioner’s arguments. Thereafter,
`Petitioner may use any time it has reserved for rebuttal only to respond to
`arguments presented by Patent Owner. Patent Owner may not reserve
`rebuttal time.
`The Board will provide a court reporter, and the reporter’s transcript
`will constitute the official record of the hearing. The hearing transcript will
`be entered in the record of this proceeding.
`Under 37 C.F.R. § 42.70(b), demonstrative exhibits must be served at
`least seven (7) business days before the hearing. The Board requests that
`such exhibits be filed at the Board at least five business days before the
`
`2
`
`
`
`IPR2016-01096
`Patent 6,667,061 B2
`
`hearing. A hard copy of the demonstratives should be provided to the court
`reporter at the hearing.
`Demonstrative exhibits are not evidence, but are merely a visual aid at
`the oral arguments. Demonstrative exhibits may not introduce new evidence
`or raise new arguments, but instead, should cite to evidence in the record.
`The parties are directed to St. Jude Medical, Cardiology Division, Inc. v. The
`Board of Regents of the University of Michigan, Case IPR2013-00041
`(PTAB Jan. 27, 2014) (Paper 65), regarding the appropriate content of
`demonstrative exhibits. The Board expects that the parties will meet and
`confer in good faith to resolve any objections to demonstrative exhibits, but
`if such objections cannot be resolved the parties may file any objections to
`demonstratives with the Board at least two business days before the hearing.
`The objections should identify with particularity which portions of the
`demonstrative exhibits are subject to objection, include a copy of the
`objected-to portions, and include a one-sentence statement of the reason for
`each objection. The Board asks the parties to confine demonstrative exhibit
`objections to those identifying egregious violations that are prejudicial to the
`administration of justice. No argument or further explanation is permitted.
`The Board will consider any objections and schedule a conference call if
`deemed necessary. Otherwise, the Board will reserve ruling on the
`objections. Any objection to demonstrative exhibits that is not timely
`presented will be considered waived.
`The parties also should note that at least one member of the panel will
`be attending the hearing electronically from a remote location, and that if a
`demonstrative is not made fully available or visible to the judge participating
`in the hearing remotely, that demonstrative will not be considered. The
`
`3
`
`
`
`IPR2016-01096
`Patent 6,667,061 B2
`
`parties are also reminded that the presenter must identify clearly and
`specifically each demonstrative exhibit (e.g., by slide or screen number)
`referenced during the hearing to ensure the clarity and accuracy of the
`reporter’s transcript and the ability of the judge participating in the hearing
`remotely to closely follow the presenter’s arguments.
`The Board expects lead counsel for each party to be present at the oral
`hearing, although any counsel of record may make the actual presentation.
`If either party anticipates that its lead counsel will not be in attendance at the
`oral hearing, the Board shall be advised by email no later than five (5)
`business days prior to the oral hearing, and such lead counsel shall be
`available to discuss the matter via conference call if necessary.
`Questions regarding specific audio-visual equipment should be
`directed to the Board at (571) 272-9797. Requests for audio-visual
`equipment are to be made (5) five days in advance of the hearing date. The
`request is to be sent to Trials@uspto.gov. If the request is not received
`timely, the equipment may not be available on the day of the hearing.
`It is
`ORDERED that oral argument will commence at 1:00 PM ET on
`August 28, 2017.
`
`
`
`
`4
`
`
`
`IPR2016-01096
`Patent 6,667,061 B2
`
`PETITIONER:
`
`William Mentlik
`Paul Kochanski
`Tedd Van Burskirk
`Nichole Valeyko
`LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP
`wmentlik.ipr@ ldlkm.com
`pkochanski@ldlkm.com
`tvanburkirk@ldlkm.com
`nvaleyko@ldlkm.com
`
`
`PATENT OWNER:
`Scott Reed
`Justin Oliver
`FITZPATRICK, CELLA, HARPER & SCINTO
`sreed@fchs.com joliver@fchs.com
`alkermesipr@fchs.com
`
`5
`
`